XOMA to Present at the Cowen & Company Health Care Conference
March 09 2016 - 7:46PM
XOMA Corporation (Nasdaq:XOMA), a leader in the discovery and
development of therapeutic antibodies, announced today Paul Rubin,
the Company’s Senior Vice President, Research and Development &
Chief Medical Officer, is scheduled to present at the Cowen and
Company Health Care Conference on Monday, March 7, 2016 at 2:40
p.m. ET.
A live audio webcast of the presentation can be
accessed in the Investors and Media section of XOMA's website at
http://investors.xoma.com/events.cfm. An archived version of the
webcast will be available via replay for 30 days following the
presentation.
About XOMA Corporation
XOMA Corporation is a leader in the discovery
and development of therapeutic antibodies. The Company's innovative
product candidates result from its expertise in developing
ground-breaking monoclonal antibodies, including allosteric
antibodies, which have created new opportunities to potentially
treat a wide range of human diseases. XOMA's scientific research
has produced a portfolio of five endocrine assets, each of which
has the opportunity to address multiple indications. The Company's
lead product candidate, XOMA 358, is an allosteric monoclonal
antibody that reduces insulin receptor activity, which could have a
major impact on the treatment of hyperinsulinism. The Company
recently initiated Phase 2 development activities for XOMA 358 in
patients with congenital hyperinsulinism. For more information,
visit www.xoma.com.
Company and Investor Contact:
Ashleigh Barreto
510-204-7482
barreto@xoma.com
Juliane Snowden
The Oratorium Group, LLC
jsnowden@oratoriumgroup.com
Media Contact:
Ryan Flinn
W2O Group
415-946-1059
rflinn@w2ogroup.com
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Mar 2024 to Apr 2024
XOMA (NASDAQ:XOMA)
Historical Stock Chart
From Apr 2023 to Apr 2024